Iterum Therapeutics plc

What they do

Iterum developed and commercializes ORLYNVAH (oral sulopenem etzadroxil-probenecid), an oral penem antibiotic approved by the FDA in October 2024 for uncomplicated urinary tract infections (uUTIs) in adult women with limited or no alternative oral options. It also has an intravenous sulopenem program that is not yet approved. The company exclusively licenses certain sulopenem patents from Pfizer and owns patents on the bilayer tablet and methods of use. Commercialization in the U.S. is supported by a Product Commercialization Agreement with EVERSANA.

Revenue drivers

• ORLYNVAH U.S. net product sales — Only revenue-generating product; launched August 2025. Third-quarter 2025 net product revenue was $0.4 million, consisting mainly of initial stocking at specialty pharmacies in targeted territories.
• CARB-X funding arrangements — The company has generated limited revenue from a funding arrangement with the Trustees of Boston University under the CARB-X program. Annual revenue was $0 in 2020 and 2021 and no material amounts are cited in later periods.
• Sulopenem IV (development stage) — Intravenous sulopenem is not approved and generates no revenue; it remains part of the sulopenem program for potential future indications.

Recent performance

Third-quarter 2025 net product revenues were $0.4 million from ORLYNVAH sales following the August 2025 launch and consisted mainly of initial specialty pharmacy stocking. Cost of sales was $0.02 million, primarily Pfizer royalty payments. Research and development expense was $1.3 million, down from $3.1 million in the prior-year quarter, mostly due to lower CMC costs as manufacturing costs shifted to inventory after approval. Amortization of the Pfizer-related intangible asset was $0.3 million. Cash and cash equivalents were $11.0 million as of September 30, 2025.

Strategy

Management is prioritizing commercialization of ORLYNVAH in the U.S. through a limited direct sales force targeting high-volume uUTI prescribers in a limited geographic area, supported by EVERSANA for sales, marketing, logistics and related services. The company also continues efforts to sell, license or otherwise dispose of its sulopenem rights to maximize stakeholder value; if no transaction occurs, it is considering commercializing on its own or with a partner. It plans to hire additional commercial personnel in marketing, patient access, analytics and distribution. It also continues patent estate expansion, including recent grants in China and Mexico.

Risks

• Going concern and limited cash runway — With $11.0 million in cash at September 30, 2025 and $2.6 million of ATM net proceeds through November 13, 2025, management expects funding only into the second quarter of 2026.
• Early-stage commercial execution — ORLYNVAH launched only in August 2025 with a limited commercial infrastructure, and management expects only modest 2025 sales, making execution uncertain.
• Strategic transaction uncertainty — The company is pursuing a sale, license or other disposition of sulopenem rights, but no transaction has been completed.
• Listing and financing risk — Recent 8-K filings report delisting notices or listing-rule failures and a bankruptcy or receivership event with an obligation acceleration triggering event, which could impair access to capital.

Outlook

For 2026, management expects net product sales of ORLYNVAH to range between $5 million and $15 million, depending on uptake and payer coverage, and will refine guidance as market dynamics evolve. The company expects continued significant expenses and increased operating losses as it commercializes ORLYNVAH and pursues additional development. Cash is expected to fund operations into the second quarter of 2026 before additional financing would be needed. Management continues to pursue a strategic transaction for its sulopenem rights.